The European Vaccine Initiative, in cooperation with University Medical Center Utrecht and GSK Vaccines, has produced an informative video giving an overview of the project, its goals, and how they will be achieved, including interviews with three key partners.
February 2025
The PrIMAVeRa project invites everyone to watch a new video that explains its objectives. The project aims to develop a tool that helps policymakers and vaccine developers evaluate different options for allocating limited resources in the fight against antimicrobial resistance (AMR). This will provide novel insights into the cost-effectiveness of various paths of prioritisation in treatment and inoculation recommendations, as well as development of new vaccines and monoclonal antibodies (mAbs).
The short film includes interviews with three key contributors to the PrIMAVeRa project:
Dr. Irina Meln, Project Coordinator, of the European Vaccine Initiative
Dr. Marc Bonten, Scientific Lead, of the University Medical Center Utrecht
Dr. Venanzio Vella, EFPIA Lead, of GSK Vaccines
This video has been accepted for presentation at this year’s European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Vienna, and project partners look forward to raising awareness of PrIMAVeRa and its unique approach to combatting antimicrobial resistance.
The PrIMAVeRa consortium invites all to view this video to gain a better understanding of the project’s place in the battle against AMR.
You can view the video here: https://www.primavera-amr.eu/
---
This work has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034420 (PrIMAVeRa). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. This communication reflects the author's view, and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.